{
    "name": "chloroquine",
    "comment": "Rx",
    "other_names": [
        "Chloroquine phosphate"
    ],
    "classes": [
        "Antimalarials",
        "Antimalarials",
        "Aminoquinolines"
    ],
    "source": "https://reference.medscape.com/drug/chloroquine-phosphate-chloroquine-342687",
    "pregnancy": {
        "common": [
            "In humans, at recommended doses for prophylaxis and treatment of malaria, observational studies as well as a meta-analysis, including a small number of prospective studies with chloroquine exposure during pregnancy, have shown no increase in the rate of birth defects or spontaneous abortions",
            "Avoid use during pregnancy except in prophylaxis or treatment of malaria when benefit outweighs potential risk to fetus"
        ],
        "specific": [
            {
                "type": "Animal data ",
                "description": [
                    "In animal studies, embryofetal developmental toxicity was shown at doses ranging from 250-1500 mg/kg body weight; approximately 3-16x the maximum recommended therapeutic dose based on a body surface area comparison",
                    "Preclinical data showed a potential risk of genotoxicity in some test systems"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Owing to the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or chloroquine, taking into account the potential clinical benefit of the drug to the mother",
            "Excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in eleven lactating mothers following a single oral dose of chloroquine (600-mg base); maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in malaria",
            "Separate prophylaxis for the infant is required"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to chloroquine, 4-aminoquinolones",
                "Psoriasis, porphyria, retinal or visual field changes"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Acute extrapyramidal disorders may occur; reactions usually resolve after treatment discontinuation and/or symptomatic treatment",
                "Not effective in most areas; CDC recommends mefloquine or atovaquone/proguanil - check CDC traveler information for specific recommendations for region",
                "May cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency; blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis",
                "Experimental data showed a potential risk of inducing gene mutations; there are insufficient data in humans to rule out an increased risk of cancer in patients receiving long-term treatment",
                "Cases of cardiomyopathy resulting in cardiac failure, in some cases with fatal outcome, have been reported in patients treated during long term therapy at high doses with chloroquine; monitor for signs and symptoms of cardiomyopathy and discontinue chloroquine if cardiomyopathy develops to prevent life-threatening complications",
                "May cause conduction disorders (eg, bundle branch block / AV heart block) are diagnosed; if cardiotoxicity is suspected, prompt discontinuation of chloroquine may prevent life-threatening complications",
                "Monitor knee and ankle reflexes in patients on long-term therapy to detect any evidence of muscular weakness; if weakness occurs, discontinue therapy",
                "A number of fatalities have been reported following the accidental ingestion of chloroquine; advise to keep medication out of the reach of children because they are especially sensitive to the 4-aminoquinoline compounds",
                "Use in patients with psoriasis may precipitate a severe attack of psoriasis; may be exacerbated condition when used in patients with porphyria; do not use in these conditions unless the benefit to the patient outweighs the potential risks",
                "Shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications; patients should be warned about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with chloroquine should have blood glucose level checked and treatment reviewed as necessary",
                "Administer with caution in patients with preexisting auditory damage; discontinue therapy immediately in case of any defects in hearing; observe patient closely",
                "Caution with hepatic disease, alcoholism, and coadministration with other hepatotoxic drugs",
                "May provoke seizures in patients with history of epilepsy",
                "Chloroquine does not treat hypnozoite liver stage forms of Plasmodium and will therefore not prevent relapses of malaria due to P. vivax or P. ovale; additional treatment with an anti-malarial agent active against these forms, such as an 8-aminoquinoline, required for treatment of infections with P. vivax and P. ovale"
            ],
            "specific": [
                {
                    "type": "Chloroquine-resistant malaria",
                    "description": [
                        "This drug is not effective against resistant strains of Plasmodium species; chloroquine resistance is widespread in P. falciparum and is reported in P. vivax",
                        "Before using chloroquine for prophylaxis, it should be ascertained whether chloroquine is appropriate for use in the region to be visited by the traveler. Information regarding the geographic areas where resistance to chloroquine occurs, is available at the Centers for Disease Control and Prevention (",
                        "www.cdc.gov\\malaria",
                        ")",
                        "Patients infected with a resistant strain of plasmodia as shown by the fact that normally adequate doses have failed to prevent or cure clinical malaria or parasitemia should be treated with another form of antimalarial therapy"
                    ]
                },
                {
                    "type": "QT prolongation",
                    "description": [
                        "QT interval prolongation, torsade de pointes, and ventricular arrhythmias have been reported ",
                        "The risk increases with higher doses chloroquine; fatal cases have been reported",
                        "Use with caution in patients with cardiac disease, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (<50 bpm)"
                    ]
                },
                {
                    "type": "Retinopathy",
                    "description": [
                        "Irreversible retinal damage observed",
                        "Significant risk factors for retinal damage include daily doses of chloroquine phosphate >2.3 mg/kg of actual body weight, durations of use >5 years, subnormal glomerular filtration, and concurrent macular disease",
                        "Perform baseline ophthalmological examination within the first year of starting chloroquine phosphate tablets",
                        "Baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain optical coherence tomography (SD-OCT)",
                        "Exams (including BCVA, VF and SD-OCT) should be monitored annually in individuals with significant risk factors and may be deferred up to 5 years for individuals without risk factors",
                        "In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees",
                        "Discontinue if ocular toxicity is suspected and closely monitor; retinal changes (and visual disturbances) may progress even after cessation of therapy"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Plasma concentrations of chloroquine and desethylchloroquine (major metabolite of chloroquine) were negatively associated with log antibody titers; the recommended dose of chloroquine for malaria prophylaxis can reduce the antibody response to primary immunization with intradermal human diploid-cell rabies vaccine",
                        "Concomitant use of chloroquine with drugs known to induce retinal toxicity such as tamoxifen is not recommended ",
                        "Risk of QT interval prolongation increases with concomitant administration of chloroquine with QT interval prolonging agents ",
                        "Effects of other drugs on chloroquine",
                        "Antacids and kaolin can reduce absorption of chloroquine; observe for at least 4 hr between intake of these agents and chloroquine ",
                        "Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level; avoid use",
                        "Chloroquine effects on other drugs",
                        "As chloroquine may enhance the effects of a hypoglycemic treatment, a decrease in doses of insulin or other antidiabetic drugs may be required.",
                        "Chloroquine significantly reduced the bioavailability of ampicillin; monitor at least 2 hr between intake of ampicillin and chloroquine",
                        "After introduction of chloroquine (oral form), a sudden increase in serum cyclosporine level has been reported; closely monitor of serum cyclosporine level and if necessary, discontinue chloroquine",
                        "May increase risk of inducing ventricular arrhythmias if chloroquine is used concomitantly with other arrhythmogenic drugs (eg, amiodarone, moxifloxacin)",
                        "In a single-dose interaction study, chloroquine has been reported to reduce the bioavailability of praziquantel ",
                        "Coadministration of chloroquine and mefloquine may increase the risk of convulsions"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "agalsidase alfa",
            "description": {
                "common": "chloroquine decreases effects of agalsidase alfa by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "agalsidase beta",
            "description": {
                "common": "chloroquine decreases effects of agalsidase beta by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "artemether",
            "description": {
                "common": "artemether increases toxicity of chloroquine by QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine increases toxicity of chloroquine by QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "chloroquine increases toxicity of clarithromycin by QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "chloroquine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lefamulin",
            "description": {
                "common": "lefamulin will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pazopanib",
            "description": {
                "common": "chloroquine increases toxicity of pazopanib by QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of chloroquine by  Other (see comment). Contraindicated. Quinidine is contraindicated in patients receiving drugs that both prolong the QT interval and are metabolized by CYP2D6, such as chloroquine"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "saquinavir",
            "description": {
                "common": "chloroquine increases toxicity of saquinavir by QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "voriconazole",
            "description": {
                "common": "chloroquine increases toxicity of voriconazole by QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amiodarone",
            "description": {
                "common": "chloroquine increases toxicity of amiodarone by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "chloroquine and amisulpride both increase  QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amlodipine",
            "description": {
                "common": "chloroquine will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "chloroquine and anagrelide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "chloroquine will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "arsenic trioxide",
            "description": {
                "common": "chloroquine increases toxicity of arsenic trioxide by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "atomoxetine and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "chloroquine increases toxicity of bedaquiline by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "chloroquine and buprenorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "buprenorphine subdermal implant and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chloroquine increases toxicity of chlorpromazine by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine increases levels of chloroquine by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisapride",
            "description": {
                "common": "chloroquine increases toxicity of cisapride by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dacomitinib",
            "description": {
                "common": "dacomitinib will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dapsone topical",
            "description": {
                "common": "chloroquine, dapsone topical. unspecified interaction mechanism. Avoid or Use Alternate Drug. Avoid coadministration of dapsone topical with oral dapsone or antimalarial medications because of the potential for hemolytic reactions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "disopyramide",
            "description": {
                "common": "chloroquine increases toxicity of disopyramide by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dofetilide",
            "description": {
                "common": "chloroquine increases toxicity of dofetilide by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dronedarone",
            "description": {
                "common": "chloroquine increases toxicity of dronedarone by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eliglustat",
            "description": {
                "common": "chloroquine and eliglustat both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "chloroquine and entrectinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eribulin",
            "description": {
                "common": "eribulin and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gilteritinib",
            "description": {
                "common": "chloroquine and gilteritinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "givosiran",
            "description": {
                "common": "givosiran will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glasdegib",
            "description": {
                "common": "chloroquine and glasdegib both increase  QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "granisetron",
            "description": {
                "common": "chloroquine and granisetron both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "chloroquine and hydroxyzine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "chloroquine decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "inotuzumab",
            "description": {
                "common": "inotuzumab and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "chloroquine and isoflurane both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lefamulin",
            "description": {
                "common": "chloroquine and lefamulin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "chloroquine and levalbuterol both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lithium",
            "description": {
                "common": "chloroquine and lithium both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loperamide",
            "description": {
                "common": "chloroquine and loperamide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "chloroquine increases toxicity of lumefantrine by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mefloquine",
            "description": {
                "common": "chloroquine, mefloquine. Mechanism: unknown. Contraindicated. Risk of convulsions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methadone",
            "description": {
                "common": "chloroquine increases toxicity of methadone by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midostaurin",
            "description": {
                "common": "chloroquine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "chloroquine and mirtazapine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olodaterol inhaled",
            "description": {
                "common": "chloroquine and olodaterol inhaled both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "chloroquine and oxaliplatin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "chloroquine and ozanimod both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "panobinostat",
            "description": {
                "common": "chloroquine and panobinostat both increase  QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "pimozide increases toxicity of chloroquine by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pitolisant",
            "description": {
                "common": "chloroquine and pitolisant both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "chloroquine and ponesimod both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primaquine",
            "description": {
                "common": "chloroquine and primaquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "procainamide",
            "description": {
                "common": "chloroquine increases toxicity of procainamide by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinidine",
            "description": {
                "common": "chloroquine increases toxicity of quinidine by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinine",
            "description": {
                "common": "chloroquine increases toxicity of quinine by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "remdesivir",
            "description": {
                "common": "chloroquine decreases effects of remdesivir by unspecified interaction mechanism. Avoid or Use Alternate Drug. Coadministration not recommended owing to antagonistic effect on remdesivir?s intracellular metabolic activation and antiviral activity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib and chloroquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "salmeterol",
            "description": {
                "common": "chloroquine and salmeterol both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selpercatinib",
            "description": {
                "common": "chloroquine and selpercatinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "chloroquine and sevoflurane both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "chloroquine and siponimod both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioridazine",
            "description": {
                "common": "chloroquine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trazodone",
            "description": {
                "common": "chloroquine and trazodone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triclabendazole",
            "description": {
                "common": "chloroquine and triclabendazole both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vandetanib",
            "description": {
                "common": "chloroquine increases toxicity of vandetanib by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voclosporin",
            "description": {
                "common": "chloroquine and voclosporin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "chloroquine increases toxicity of ziprasidone by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abiraterone",
            "description": {
                "common": "abiraterone increases levels of chloroquine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "albuterol and chloroquine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide will decrease the level or effect of chloroquine by  cation binding in GI tract. Use Caution/Monitor. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "chloroquine increases toxicity of amitriptyline by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "chloroquine increases toxicity of amoxapine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ampicillin",
            "description": {
                "common": "chloroquine decreases levels of ampicillin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate doses by at least 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apomorphine",
            "description": {
                "common": "chloroquine increases toxicity of apomorphine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "chloroquine increases toxicity of arformoterol by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "chloroquine increases toxicity of asenapine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and chloroquine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate will decrease the level or effect of chloroquine by  cation binding in GI tract. Use Caution/Monitor. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "chloroquine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azithromycin",
            "description": {
                "common": "azithromycin increases toxicity of chloroquine by QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "chloroquine will increase the level or effect of benzhydrocodone/acetaminophen by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone [benzhydrocodone is prodrug of hydrocodone]) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "chloroquine will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "chloroquine, bupivacaine implant.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate will decrease the level or effect of chloroquine by  cation binding in GI tract. Use Caution/Monitor. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "chloroquine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "chloroquine decreases effects of cholera vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune responses to cholera vaccine may be diminished when it is coadministered with chloroquine. Administer cholera vaccine at least 10 days before beginning antimalarial prophylaxis with chloroquine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "chloroquine and ciprofloxacin both increase  QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "chloroquine increases toxicity of citalopram by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "clobazam will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clofazimine",
            "description": {
                "common": "chloroquine increases toxicity of clofazimine by QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "chloroquine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "chloroquine increases toxicity of clozapine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "chloroquine will increase the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib increases levels of chloroquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of chloroquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "chloroquine increases levels of cyclosporine by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "chloroquine increases toxicity of dasatinib by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "chloroquine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "chloroquine increases toxicity of deutetrabenazine by QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolasetron",
            "description": {
                "common": "chloroquine increases toxicity of dolasetron by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "chloroquine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "chloroquine increases toxicity of droperidol by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "duvelisib will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. will increase the level or effect of"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat increases levels of chloroquine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of chloroquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, chloroquine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "chloroquine increases toxicity of erythromycin base by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "chloroquine increases toxicity of erythromycin ethylsuccinate by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "chloroquine increases toxicity of erythromycin lactobionate by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "chloroquine increases toxicity of erythromycin stearate by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "chloroquine increases toxicity of escitalopram by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "chloroquine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "chloroquine increases toxicity of fluconazole by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "chloroquine and fostemsavir both increase  QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gadobenate",
            "description": {
                "common": "chloroquine and gadobenate both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "chloroquine increases toxicity of gemifloxacin by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemtuzumab",
            "description": {
                "common": "chloroquine and gemtuzumab both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "goserelin",
            "description": {
                "common": "goserelin increases toxicity of chloroquine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haemophilus influenzae type b vaccine",
            "description": {
                "common": "chloroquine decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "chloroquine will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "histrelin",
            "description": {
                "common": "histrelin increases toxicity of chloroquine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "chloroquine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "chloroquine will increase the level or effect of hydromorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "chloroquine will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "chloroquine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, recombinant",
            "description": {
                "common": "chloroquine decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "inotuzumab",
            "description": {
                "common": "chloroquine increases toxicity of inotuzumab by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "chloroquine increases toxicity of isradipine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lanthanum carbonate",
            "description": {
                "common": "lanthanum carbonate decreases levels of chloroquine by cation binding in GI tract. Use Caution/Monitor. Administer chlorquine at least 2 hr before or after lanthanum."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenvatinib",
            "description": {
                "common": "chloroquine and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leuprolide",
            "description": {
                "common": "leuprolide increases toxicity of chloroquine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "chloroquine increases toxicity of levofloxacin by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "chloroquine will increase the level or effect of lofepramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofexidine",
            "description": {
                "common": "chloroquine increases toxicity of lofexidine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "chloroquine increases toxicity of lopinavir by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "lorcaserin will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magaldrate",
            "description": {
                "common": "magaldrate will decrease the level or effect of chloroquine by  Mechanism: inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "magnesium hydroxide will decrease the level or effect of chloroquine by  Mechanism: inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "magnesium oxide will decrease the level or effect of chloroquine by  cation binding in GI tract. Use Caution/Monitor. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "chloroquine decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "chloroquine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "chloroquine will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "chloroquine will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirabegron",
            "description": {
                "common": "mirabegron will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of chloroquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "chloroquine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "chloroquine increases toxicity of moxifloxacin by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "chloroquine will increase the level or effect of nebivolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "chloroquine increases toxicity of nilotinib by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "chloroquine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, chloroquine.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "chloroquine increases toxicity of olanzapine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "chloroquine and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "chloroquine will increase the level or effect of oliceridine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "omaveloxolone will decrease the level or effect of chloroquine by  Other (see comment). Use Caution/Monitor. Omaveloxolone may reduce systemic exposure of sensitive CYP2C8 substrates. Check prescribing information of substrate if dosage modification is needed.  "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ondansetron",
            "description": {
                "common": "chloroquine increases toxicity of ondansetron by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "osilodrostat and chloroquine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osimertinib",
            "description": {
                "common": "chloroquine increases toxicity of osimertinib by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin will increase the level or effect of chloroquine by  Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "chloroquine will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "chloroquine will increase the level or effect of oxymorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "chloroquine increases toxicity of paliperidone by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium bicarbonate",
            "description": {
                "common": "potassium bicarbonate will decrease the level or effect of chloroquine by  Mechanism: inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "chloroquine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "chloroquine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "chloroquine increases toxicity of quetiapine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "chloroquine increases toxicity of ranolazine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "chloroquine increases toxicity of ribociclib by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "chloroquine increases toxicity of risperidone by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rolapitant",
            "description": {
                "common": "rolapitant will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "romidepsin",
            "description": {
                "common": "chloroquine increases toxicity of romidepsin by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir, chloroquine.\nEither increases toxicity of the other by QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available. Increased risk of QT prolongation and cardiac arrhythmias."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "chloroquine decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "sodium bicarbonate will decrease the level or effect of chloroquine by  Mechanism: inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate doses by at least 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "chloroquine and sotalol both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, chloroquine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "chloroquine increases toxicity of tacrolimus by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "chloroquine decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "chloroquine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbinafine",
            "description": {
                "common": "terbinafine will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracaine",
            "description": {
                "common": "tetracaine, chloroquine. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "chloroquine increases toxicity of thioridazine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "chloroquine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and chloroquine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "toremifene",
            "description": {
                "common": "chloroquine increases toxicity of toremifene by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "chloroquine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "treosulfan",
            "description": {
                "common": "treosulfan decreases effects of chloroquine by Mechanism: unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triptorelin",
            "description": {
                "common": "triptorelin increases toxicity of chloroquine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "valbenazine and chloroquine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "chloroquine increases toxicity of vemurafenib by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "chloroquine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "chloroquine decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "chloroquine and alfuzosin both increase  QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anthrax vaccine",
            "description": {
                "common": "chloroquine decreases effects of anthrax vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "chloroquine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "chloroquine increases toxicity of artemether/lumefantrine by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "chloroquine decreases effects of BCG vaccine live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chloroquine will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "degarelix",
            "description": {
                "common": "chloroquine increases toxicity of degarelix by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "chloroquine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "chloroquine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "chloroquine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphtheria & tetanus toxoids",
            "description": {
                "common": "chloroquine decreases effects of diphtheria & tetanus toxoids by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphtheria & tetanus toxoids/ acellular pertussis vaccine",
            "description": {
                "common": "chloroquine decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine",
            "description": {
                "common": "chloroquine decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "chloroquine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "duloxetine",
            "description": {
                "common": "chloroquine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "encainide",
            "description": {
                "common": "chloroquine will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eribulin",
            "description": {
                "common": "chloroquine increases toxicity of eribulin by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ezogabine",
            "description": {
                "common": "chloroquine increases toxicity of ezogabine by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "chloroquine will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "chloroquine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "chloroquine will increase the level or effect of fluphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "formoterol",
            "description": {
                "common": "chloroquine increases toxicity of formoterol by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "foscarnet",
            "description": {
                "common": "chloroquine increases toxicity of foscarnet by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "galantamine",
            "description": {
                "common": "chloroquine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hepatitis A vaccine inactivated",
            "description": {
                "common": "chloroquine decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hepatitis a/b vaccine",
            "description": {
                "common": "chloroquine decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hepatitis a/typhoid vaccine",
            "description": {
                "common": "chloroquine decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hepatitis b vaccine",
            "description": {
                "common": "chloroquine decreases effects of hepatitis b vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "human papillomavirus vaccine, nonavalent",
            "description": {
                "common": "chloroquine decreases effects of human papillomavirus vaccine, nonavalent by pharmacodynamic antagonism. Minor/Significance Unknown. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "human papillomavirus vaccine, quadrivalent",
            "description": {
                "common": "chloroquine decreases effects of human papillomavirus vaccine, quadrivalent by pharmacodynamic antagonism. Minor/Significance Unknown. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "chloroquine increases toxicity of hydroxychloroquine sulfate by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibutilide",
            "description": {
                "common": "chloroquine increases toxicity of ibutilide by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iloperidone",
            "description": {
                "common": "chloroquine increases toxicity of iloperidone by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indacaterol, inhaled",
            "description": {
                "common": "chloroquine increases toxicity of indacaterol, inhaled by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "chloroquine increases toxicity of indapamide by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "chloroquine decreases effects of influenza virus vaccine quadrivalent, cell-cultured by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "chloroquine decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "influenza virus vaccine trivalent",
            "description": {
                "common": "chloroquine decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "Japanese encephalitis virus vaccine",
            "description": {
                "common": "chloroquine decreases effects of Japanese encephalitis virus vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lapatinib",
            "description": {
                "common": "chloroquine increases toxicity of lapatinib by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loratadine",
            "description": {
                "common": "chloroquine will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maprotiline",
            "description": {
                "common": "chloroquine increases toxicity of maprotiline by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "chloroquine decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "chloroquine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "chloroquine decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mefloquine",
            "description": {
                "common": "chloroquine increases toxicity of mefloquine by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meningococcal A C Y and W-135 polysaccharide vaccine combined",
            "description": {
                "common": "chloroquine decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mifepristone",
            "description": {
                "common": "chloroquine increases toxicity of mifepristone by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "octreotide",
            "description": {
                "common": "chloroquine increases toxicity of octreotide by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "chloroquine increases toxicity of ofloxacin by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxycodone",
            "description": {
                "common": "chloroquine decreases effects of oxycodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of oxycodone to active metabolite morphine."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paroxetine",
            "description": {
                "common": "chloroquine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pasireotide",
            "description": {
                "common": "chloroquine increases toxicity of pasireotide by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentamidine",
            "description": {
                "common": "chloroquine increases toxicity of pentamidine by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perhexiline",
            "description": {
                "common": "chloroquine will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perphenazine",
            "description": {
                "common": "chloroquine will increase the level or effect of perphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "chloroquine increases toxicity of pimavanserin by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pneumococcal vaccine 13-valent",
            "description": {
                "common": "chloroquine decreases effects of pneumococcal vaccine 13-valent by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pneumococcal vaccine heptavalent",
            "description": {
                "common": "chloroquine decreases effects of pneumococcal vaccine heptavalent by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pneumococcal vaccine polyvalent",
            "description": {
                "common": "chloroquine decreases effects of pneumococcal vaccine polyvalent by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "posaconazole",
            "description": {
                "common": "chloroquine increases toxicity of posaconazole by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "praziquantel",
            "description": {
                "common": "chloroquine decreases levels of praziquantel by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primaquine",
            "description": {
                "common": "primaquine, chloroquine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hemolysis in G6PD deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "chloroquine will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promazine",
            "description": {
                "common": "chloroquine will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promethazine",
            "description": {
                "common": "chloroquine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protriptyline",
            "description": {
                "common": "chloroquine increases toxicity of protriptyline by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rabies vaccine",
            "description": {
                "common": "chloroquine decreases effects of rabies vaccine by pharmacodynamic antagonism. Minor/Significance Unknown. Immunosuppressants may interfere with development of active immunity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rabies vaccine chick embryo cell derived",
            "description": {
                "common": "chloroquine decreases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "chloroquine increases toxicity of rilpivirine by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "risperidone",
            "description": {
                "common": "chloroquine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "chloroquine decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "chloroquine decreases effects of rubella vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sertraline",
            "description": {
                "common": "chloroquine increases toxicity of sertraline by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "chloroquine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "solifenacin",
            "description": {
                "common": "chloroquine increases toxicity of solifenacin by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sorafenib",
            "description": {
                "common": "chloroquine increases toxicity of sorafenib by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sunitinib",
            "description": {
                "common": "chloroquine increases toxicity of sunitinib by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "chloroquine increases levels of tacrolimus by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "telavancin",
            "description": {
                "common": "chloroquine increases toxicity of telavancin by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tetanus toxoid adsorbed or fluid",
            "description": {
                "common": "chloroquine decreases effects of tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "chloroquine increases toxicity of tetrabenazine by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thioridazine",
            "description": {
                "common": "chloroquine increases levels of thioridazine by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiothixene",
            "description": {
                "common": "chloroquine increases toxicity of thiothixene by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tick-borne encephalitis vaccine",
            "description": {
                "common": "chloroquine decreases effects of tick-borne encephalitis vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolterodine",
            "description": {
                "common": "chloroquine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "travelers diarrhea and cholera vaccine inactivated",
            "description": {
                "common": "chloroquine decreases effects of travelers diarrhea and cholera vaccine inactivated by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "chloroquine will increase the level or effect of trifluoperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimipramine",
            "description": {
                "common": "chloroquine increases toxicity of trimipramine by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tropisetron",
            "description": {
                "common": "chloroquine will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "typhoid polysaccharide vaccine",
            "description": {
                "common": "chloroquine decreases effects of typhoid polysaccharide vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "chloroquine decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vardenafil",
            "description": {
                "common": "chloroquine increases toxicity of vardenafil by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "chloroquine decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vorinostat",
            "description": {
                "common": "chloroquine increases toxicity of vorinostat by QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "chloroquine decreases effects of yellow fever vaccine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "chloroquine decreases effects of zoster vaccine live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Ocular disorders",
            "percent": "6"
        },
        {
            "name": "Maculopathy",
            "percent": null
        },
        {
            "name": "macular degeneration",
            "percent": null
        },
        {
            "name": "visual disturbances",
            "percent": null
        },
        {
            "name": "nyctalopia",
            "percent": null
        },
        {
            "name": "scotomatous vision with field defects of paracentral",
            "percent": null
        },
        {
            "name": "pericentral ring types",
            "percent": null
        },
        {
            "name": "typically temporal scotomas",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "difficulty in reading with words tending to disappear",
            "percent": null
        },
        {
            "name": "seeing half an object",
            "percent": null
        },
        {
            "name": "misty vision",
            "percent": null
        },
        {
            "name": "and fog before the eyes",
            "percent": null
        },
        {
            "name": "reversible corneal opacities",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "anaphylactic reaction",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "Ear and labyrinth disorders",
            "percent": null
        },
        {
            "name": "Nerve type deafness",
            "percent": null
        },
        {
            "name": "tinnitus",
            "percent": null
        },
        {
            "name": "reduced hearing in patients with preexisting auditory damage",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue",
            "percent": null
        },
        {
            "name": "disorders",
            "percent": null
        },
        {
            "name": "Sensorimotor disorders",
            "percent": null
        },
        {
            "name": "skeletal muscle myopathy or neuromyopathy",
            "percent": null
        },
        {
            "name": "depression of tendon reflexes",
            "percent": null
        },
        {
            "name": "abnormal nerve conduction",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "increased liver enzymes",
            "percent": null
        },
        {
            "name": "anorexia",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "abdominal cramps",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Stevens Johnson syndrome",
            "percent": null
        },
        {
            "name": "toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "pleomorphic skin eruptions",
            "percent": null
        },
        {
            "name": "skin and mucosal pigment changes",
            "percent": null
        },
        {
            "name": "lichen planus",
            "percent": null
        },
        {
            "name": "like eruptions",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "drug rash with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "DRESS syndrome",
            "percent": null
        },
        {
            "name": "photosensitivity",
            "percent": null
        },
        {
            "name": "hair loss",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Pancytopenia",
            "percent": null
        },
        {
            "name": "aplastic anemia",
            "percent": null
        },
        {
            "name": "reversible agranulocytosis",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "neutropenia",
            "percent": null
        },
        {
            "name": "hemolytic anemia in G",
            "percent": null
        },
        {
            "name": "PD deficient patients",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Convulsions",
            "percent": null
        },
        {
            "name": "mild and transient headache",
            "percent": null
        },
        {
            "name": "polyneuropathy",
            "percent": null
        },
        {
            "name": "acute extrapyramidal disorders",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "dystonia",
            "percent": null
        },
        {
            "name": "dyskinesia",
            "percent": null
        },
        {
            "name": "tongue protrusion",
            "percent": null
        },
        {
            "name": "torticollis",
            "percent": null
        },
        {
            "name": "Neuropsychiatric disorders",
            "percent": null
        },
        {
            "name": "Psychosis",
            "percent": null
        },
        {
            "name": "delirium",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "agitation",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "confusion",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "personality changes",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "suicidal behavior",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "ECG changes",
            "percent": null
        },
        {
            "name": "particularly",
            "percent": null
        },
        {
            "name": "inversion or depression of the T",
            "percent": null
        },
        {
            "name": "wave with widening of the QRS complex",
            "percent": null
        },
        {
            "name": "cardiomyopathy",
            "percent": null
        },
        {
            "name": "cardiac arrhythmias",
            "percent": null
        },
        {
            "name": "conduction disorders",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "bundle branch block",
            "percent": null
        },
        {
            "name": "atrioventricular",
            "percent": null
        },
        {
            "name": "AV",
            "percent": null
        },
        {
            "name": "block",
            "percent": null
        },
        {
            "name": "QT interval prolongation",
            "percent": null
        },
        {
            "name": "torsade de pointes",
            "percent": null
        },
        {
            "name": "ventricular tachycardia",
            "percent": null
        },
        {
            "name": "ventricular fibrillation",
            "percent": null
        },
        {
            "name": "Metabolic and nutritional disorders",
            "percent": null
        },
        {
            "name": "Hypoglycemia",
            "percent": null
        }
    ]
}